<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04387695</url>
  </required_header>
  <id_info>
    <org_study_id>HEPIC2001</org_study_id>
    <nct_id>NCT04387695</nct_id>
  </id_info>
  <brief_title>SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT</brief_title>
  <official_title>SBRT Sequential TACE Combined With Sorafenib Versus Sorafenib Alone in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus：A Single-center Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital of Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate and compare the efficacy and safety of SBRT sequential TACE combined with
      sorafenib versus sorafenib alone in the treatment of unreactable HCC with PVTT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      HCC Patients classified as BCLC stage C present with PVTT, and the recommended first-line
      treatment is systemic therapy with sorafenib according to updated Barcelona Clinical Liver
      cancer (BCLC) treatment algorithms.However, recent data from observational studies suggest
      that the combination of TACE and SBRT would be as effective as sorafenib.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS) rate</measure>
    <time_frame>at 12 weeks after randomization</time_frame>
    <description>Progression is defined as progressive disease (PD) by independent radiologic review according to mRECIST criteria, termination of the assigned treatment, or death from any cause, assessed by Kaplan-Meier analysis and log-rank test for treatment comparisons with the intention-to-treat principle.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiologic response rate</measure>
    <time_frame>at 12 weeks after randomization</time_frame>
    <description>Radiologic response rate by independent radiologic review according to mRECIST criteria , assessed by Chi-square test or Fisher's exact test, as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall patient survival rate</measure>
    <time_frame>up to 2 years after randomization</time_frame>
    <description>The median overall patient survival rate assessed by Kaplan-Meier analysis and log-rank test for treatment comparisons.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>at 12 weeks and up to 2 years after randomization</time_frame>
    <description>Objective response rate by independent radiologic review according to mRECIST criteria , assessed by Chi-square test or Fisher's exact test, as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>at 12 weeks and up to 2 years after randomization</time_frame>
    <description>Disease control rate by independent radiologic review according to mRECIST criteria , assessed by Chi-square test or Fisher's exact test, as appropriate.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Unresectable Hepatocellular Carcinoma</condition>
  <condition>Portal Vein Thrombosis</condition>
  <arm_group>
    <arm_group_label>SBRT + TACE + Sorafenib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SBRT sequential TACE combined with Sorafenib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sorafenib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sorafenib 800 mg/day orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>SBRT+TACE+Sorafenib</intervention_name>
    <description>SBRT first for the PVTT +TACE for HCC within a week next +Sorafenib with 2 weeks later</description>
    <arm_group_label>SBRT + TACE + Sorafenib</arm_group_label>
    <other_name>Stereotactic Body Radiation Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <description>Sorafenib 800 mg/day orally</description>
    <arm_group_label>Sorafenib</arm_group_label>
    <other_name>Nexavar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Child-Pugh score ≤ 7

          -  Performance status: ECOG score ≤ 2

          -  HCC diagnosed by biopsy or by the noninvasive criteria of the Chinese Liver Cancer
             Guideline 2017

          -  the primary HCC being unresectable (BCLC C stage/ CNLC Ⅲa-b) according to NCCN
             guideline

          -  No previous therapy for HCC

          -  at least one measurable target lesion according to RECIST 1.1

          -  Adequate hematopoietic function: Hemoglobin ≥ 8.5 g/dL; Absolute neutrophil count ≥
             750/mm3; Platelet count ≥ 50,000/mm3

          -  Serum total bilirubin ≤ 2 x ULN

          -  Aspartate aminotransferase (AST) and alanine aminotransferase ≤ 10 x ULN

          -  Creatinine ≤ 1.5 x ULN

          -  No plan for pregnancy or breast feeding. Active contraception.

          -  Willing to give informed consent

        Exclusion Criteria:

          -  Prior history to or exposure of transarterial chemoembolization, external beam
             radiation to liver, or sorafenib

          -  Complete obstruction of hepatic outflow

          -  Uncontrolled ascites of hepatic encephalopathy

          -  Prior liver transplantation

          -  Positive for human immunodeficiency virus (HIV)

          -  Active gastric or duodenal ulcer

          -  Other uncontrolled comorbidities or malignancy

          -  Inability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun-hui Sun, MD,PH.D</last_name>
    <role>Study Director</role>
    <affiliation>First Affiliated Hospital of Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun-hui Sun, MD,PH.D</last_name>
    <phone>+86-0571-87236815</phone>
    <email>1307005@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tan-yang Zhou, MD,PH.D</last_name>
    <phone>+86-0571-87236812</phone>
    <email>zhoutanyang@zju.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital, College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun-hui Sun, MD,PH.D</last_name>
      <phone>+86-0571-87236815</phone>
      <email>1307005@zju.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Tan-yang Zhou, MD,PH.D</last_name>
      <phone>+86-0571-87236812</phone>
      <email>zhoutanyang@zju.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma,Portal Vein Tumor Thrombus</keyword>
  <keyword>Radiation ,Sorafenib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

